Kineta Inc

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Mercer Island, WA.

NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kineta, Inc. (OTC: KANT ), relating to the proposed merger with TuHURA Biosciences, Inc. Under the terms of the agreement, TuHURA would acquire the rights to Kineta's novel KVA12123 antibody for a combination of cash and shares of TuHURA common stock.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kineta, Inc. (OTC PINK: KANT) and TuHURA Biosciences, Inc. is fair to Kineta shareholders. Halper Sadeh encourages Kineta shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Kineta and its board violated the fede.

KANT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kineta, Inc. Is Fair to Shareholders

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end.

Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually.

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer SEATTLE, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that TuHURA Biosciences Inc (TuHURA) is exercising its right to extend their exclusivity and right of first offer agreement (the “Agreement”) for Kineta's VISTA blocking antibody KVA12123.

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

Kineta will be trading under the symbol “KANT” on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right of first offer for Kineta's KVA12123 program The ongoing KVA12123 Phase 1 study is open for new patient enrollment and following those patients previously enrolled. SEATTLE, Sept.

Kineta, Inc Transitioning from Nasdaq to OTC Markets

News for Kineta Inc Stock (KANT)